ATE326468T1 - Pyridon-kondensierte azabicyclische- oder cytisin-derivate, ihre herstellung und verwendung in der suchttherapie - Google Patents

Pyridon-kondensierte azabicyclische- oder cytisin-derivate, ihre herstellung und verwendung in der suchttherapie

Info

Publication number
ATE326468T1
ATE326468T1 AT97942166T AT97942166T ATE326468T1 AT E326468 T1 ATE326468 T1 AT E326468T1 AT 97942166 T AT97942166 T AT 97942166T AT 97942166 T AT97942166 T AT 97942166T AT E326468 T1 ATE326468 T1 AT E326468T1
Authority
AT
Austria
Prior art keywords
azabicyclic
pyridone
condensed
preparation
addiction therapy
Prior art date
Application number
AT97942166T
Other languages
English (en)
Inventor
Brian Thomas O'neill
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Application granted granted Critical
Publication of ATE326468T1 publication Critical patent/ATE326468T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Psychology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
AT97942166T 1996-10-30 1997-10-15 Pyridon-kondensierte azabicyclische- oder cytisin-derivate, ihre herstellung und verwendung in der suchttherapie ATE326468T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US2880496P 1996-10-30 1996-10-30

Publications (1)

Publication Number Publication Date
ATE326468T1 true ATE326468T1 (de) 2006-06-15

Family

ID=21845528

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97942166T ATE326468T1 (de) 1996-10-30 1997-10-15 Pyridon-kondensierte azabicyclische- oder cytisin-derivate, ihre herstellung und verwendung in der suchttherapie

Country Status (17)

Country Link
US (2) US6235734B1 (de)
EP (1) EP0937077B1 (de)
JP (2) JP3621707B2 (de)
AP (1) AP9701125A0 (de)
AR (1) AR008901A1 (de)
AT (1) ATE326468T1 (de)
AU (1) AU4394897A (de)
DE (1) DE69735891T2 (de)
ES (1) ES2264169T3 (de)
GT (1) GT199700115A (de)
HR (1) HRP970567A2 (de)
ID (1) ID18741A (de)
MA (1) MA26445A1 (de)
PA (1) PA8440201A1 (de)
TN (1) TNSN97168A1 (de)
WO (1) WO1998018798A1 (de)
ZA (1) ZA979706B (de)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6717030B2 (en) * 1998-07-06 2004-04-06 The Regents Of The University Of California Protein kinase C epsilon as modulator of anxiety, alcohol consumption and self-administration of drugs of abuse
IL137937A0 (en) * 1999-08-27 2001-10-31 Pfizer Prod Inc A pharmaceutical composition for the prevention and treatment of nicotine addiction in a mammal
US20010036943A1 (en) * 2000-04-07 2001-11-01 Coe Jotham W. Pharmaceutical composition for treatment of acute, chronic pain and/or neuropathic pain and migraines
US20020010192A1 (en) * 2000-06-02 2002-01-24 Coe Jotham Wadsworth Pharmaceutical composition for the treatment of obesity or to facilitate or promote weight loss
US20020016334A1 (en) * 2000-07-31 2002-02-07 Coe Jotham Wadsworth Pharmaceutical composition for the treatment of attention deficit hyperactivity disorder (ADHD)
PL369886A1 (en) 2001-11-30 2005-05-02 Pfizer Products Inc. Aryl fused azapolycyclic compounds
SE0104463D0 (sv) * 2001-12-29 2001-12-29 Carlbiotech Ltd As Mellanprodukter för syntes af LHRH-antagonister, sätt att framställa dem och sätt för framställning av LHRH-antagonister
US20030162770A1 (en) 2002-02-22 2003-08-28 Davis Bonnie M. Use of modulators of nicotinic receptors for treatment of cognitive dysfunction
US20040224962A1 (en) * 2003-05-09 2004-11-11 Pfizer Inc Pharmaceutical composition for the treatment of obesity or to facilitate or promote weight loss
US20040224963A1 (en) * 2003-05-09 2004-11-11 Pfizer Inc Pharmaceutical composition for the prevention and treatment of nicotine addiction in a mammal
US8030300B2 (en) 2003-06-10 2011-10-04 Georgetown University Ligands for nicotinic acetylcholine receptors, and methods of making and using them
DE602004023299D1 (de) 2003-07-21 2009-11-05 Pfizer Prod Inc Nikotin abhängigkeit reduzierende heteroaryl kondensierte azapolycyclische verbindungen
US20050234024A1 (en) * 2004-04-14 2005-10-20 Clarke David E Materials and methods for the treatment of ulcerative colitis
US7135933B2 (en) * 2004-09-29 2006-11-14 Intelliserv, Inc. System for adjusting frequency of electrical output pulses derived from an oscillator
CA2591330A1 (en) * 2004-12-07 2006-06-15 Pfizer Products Inc. 1, 2, 3, 3a, 8, 8a-hexahydro-2, 7a-diada-cyclopenta [a] inden-7-one derivatives which bind to neuronal nicotinic acetylcholine specific receptor sites and are useful in modulatingcholinergic function and in the treatment of addictive disorders
US20060211649A1 (en) * 2005-03-21 2006-09-21 Eric Marchewitz Use of cytisine for enhancing physical performance
US20070134169A1 (en) * 2005-12-11 2007-06-14 Rabinoff Michael D Methods for smoking cessation or alcohol cessation or other addiction cessation
US20090318491A1 (en) * 2006-01-27 2009-12-24 Yale Univeristy Cytisine and Acetylcholine Analogs and Methods of Treating Mood Disorders
WO2007115092A2 (en) * 2006-03-29 2007-10-11 Georgetown University 10-substituted cytisine derivatives and methods of use thereof
US7404725B2 (en) * 2006-07-03 2008-07-29 Hall David R Wiper for tool string direct electrical connection
US8061443B2 (en) * 2008-04-24 2011-11-22 Schlumberger Technology Corporation Downhole sample rate system
MX368365B (es) 2009-12-22 2019-09-30 Avon Prod Inc Composiciones estimuladoras de paxilina y usos cosmeticos de las mismas.
US20110159125A1 (en) 2009-12-29 2011-06-30 Avon Products, Inc. CGRP Compositions and Uses Thereof
FR2992315B1 (fr) * 2012-06-25 2014-08-08 Pf Medicament Derives utiles dans le traitement de maladies du systeme nerveux central
CA2891122C (en) 2012-11-14 2021-07-20 The Johns Hopkins University Methods and compositions for treating schizophrenia
CN102952134B (zh) * 2012-12-05 2015-01-07 苏州药明康德检测检验有限责任公司 含二氟甲基的金雀花碱衍生物及制备方法和抗癌作用研究
RU2630958C2 (ru) * 2015-12-29 2017-09-15 федеральное государственное автономное образовательное учреждение высшего образования "Московский физико-технический институт (государственный университет)" (МФТИ) Новые макроциклические соединения, содержащие природное 3,7-диазабицикло[3.3.1]нонановое ядро и способ их получения
GB201602145D0 (en) 2016-02-05 2016-03-23 Achieve Pharma Uk Ltd Salt
CN110088106A (zh) 2016-08-19 2019-08-02 布里斯托大学 化合物
CA3070055A1 (en) * 2017-07-24 2019-01-31 Achieve Pharma Uk Limited Cytisine salts
US11083715B2 (en) * 2019-09-12 2021-08-10 Achieve Life Sciences, Inc. Compositions comprising cytisine in the treatment and/or prevention of addiction in subjects in need thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3332429T1 (de) * 1982-02-22 1984-01-26 Belorusskij naučno-issledovatel'skij sanitarno-gigieničeskij institut, 220012 Minsk Arzneipraeparat mit antinikotinwirkung und verfahren zu seiner herstellung
US4835162A (en) * 1987-02-12 1989-05-30 Abood Leo G Agonists and antagonists to nicotine as smoking deterents
US5242916A (en) * 1992-07-07 1993-09-07 R. J. Reynolds Tobacco Company Method for treatment of neurodegenerative diseases
TW261531B (de) * 1993-10-28 1995-11-01 Dynagen Inc
JPH11512443A (ja) * 1995-09-22 1999-10-26 ノボ ノルディスク アクティーゼルスカブ 新規な置換アザ環式またはアザ二環式化合物

Also Published As

Publication number Publication date
AP9701125A0 (en) 1997-10-31
US6630467B2 (en) 2003-10-07
ZA979706B (en) 1999-04-29
JP2000505809A (ja) 2000-05-16
US20030065173A1 (en) 2003-04-03
PA8440201A1 (es) 2000-05-24
JP3621707B2 (ja) 2005-02-16
ID18741A (id) 1998-05-07
TNSN97168A1 (fr) 2005-03-15
EP0937077A1 (de) 1999-08-25
GT199700115A (es) 1999-04-20
DE69735891D1 (de) 2006-06-22
JP2005060403A (ja) 2005-03-10
AR008901A1 (es) 2000-02-23
AU4394897A (en) 1998-05-22
HRP970567A2 (en) 1998-10-31
US6235734B1 (en) 2001-05-22
MA26445A1 (fr) 2004-12-20
WO1998018798A1 (en) 1998-05-07
ES2264169T3 (es) 2006-12-16
EP0937077B1 (de) 2006-05-17
DE69735891T2 (de) 2006-12-14

Similar Documents

Publication Publication Date Title
ATE326468T1 (de) Pyridon-kondensierte azabicyclische- oder cytisin-derivate, ihre herstellung und verwendung in der suchttherapie
ATE258549T1 (de) Oxazolidindion-derivate, ihre herstellung und verwendung
DE59810448D1 (de) Pyrazol-Derivate, ihre Herstellung und ihre Verwendung in Arzneimitteln
EE9800459A (et) Spiro-piperidiini derivaadid ja nende kasutamine terapeutiliste toimeainetena
DE10399006I2 (de) Tetracyclische Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung.
DE69901177D1 (de) Platinkomplex, dessen herstellung und dessen therapeutische verwendung
EE9600172A (et) Puriin-6-ooni derivaadid, nende valmistamismeetod, kasutamine ravimite valmistamiseks ja ravimid
FI944600A (fi) Imidatsol-4-yylipiperidiinijohdannaisia, niiden valmistus ja niiden käyttö terapiassa
DE59703980D1 (de) Reaktivfarbstoffe, ihre Herstellung und Verwendung
DE69713124T2 (de) 1H-PYRIDO[3,4-b]INDOLCARBOXAMIDDERIVATE, IHRE HERSTELLUNG UND THERAPEUTISCHE VERWENDUNG
DE69027170T2 (de) Uracilderivate, ihre Herstellung und ihre Verwendung
EE9900218A (et) 1,4-diasabitsüklo[2.2.2]okt-2-üülmetüülbensoaadi derivaadid, nende valmistamine ja kasutamine raviks
ATE212346T1 (de) 3-substituierte tetrahydropyridopyrimidinon- derivate, ihre herstellung und verwendung
EE200000056A (et) 4-okso-3,5-dihüdro-4H-püridasino[4.5-b]indool-1-etaanamiidi derivaadid, nende valmistamine ja kasutamine raviks
FI940186A0 (fi) 9H-imidatso/1,2-a/bentsimidatsoli-3-asetamidijohdannaisia, niiden valmistus ja niiden käyttö terapiassa
DE69735123D1 (de) Trehalose phosphorylase, deren Herstellung und Verwendung
IL126539A (en) Pregnane derivatives with no alpha-17 substituent, their medicinal use and manufacturing method
DE59501950D1 (de) Isolongifolanol-Derivate, ihre Herstellung und ihre Verwendung
EE9800333A (et) Uued furaandiarüülmetülideeni derivaadid, nende valmistamise meetod ja kasutamine teraapias
EE200000207A (et) 8-asabitsüklo[3.2.1]oktaan-3-metaanamiini derivaadid, nende valmistamine ja terapeutiline kasutamine
IL133536A0 (en) 6-pyrrolidin-2-ylpyridine derivatives, their preparation and application in therapy
ZA982369B (en) Dihydropyrazino[1,2-a]indol-1-one derivatives their preparation and their use in therapy
DE59703007D1 (de) Reaktivfarbstoffe, ihre Herstellung und Verwendung
DE69730766D1 (de) Maltooligosyltaranose und Maltooligosylparatinose enthaltende Polysaccharidzusammensetzung, Herstellung und Verwendung
EE9800396A (et) 3-[(1,2,3,4-tetrahüdroisokinolin-2-üül)metüül]-8-asabitsüklo[3,2,1]oktaani derivaadid, nende valmistamine ja kasutamine ravis

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties